How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

585 results for

Free Thyroxine Index

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Association Between Thyroid Function and Development of Different Obesity Phenotypes in Euthyroid Adults: A Nine-Year Follow-Up. (PubMed)

population-based cohort study, the Tehran Thyroid Study. Participants were categorized into four obesity phenotypes based on body mass index and metabolic status. To investigate the associations of thyrotropin and free thyroxine (fT4) with incidence of different obesity phenotypes across the study period, a multivariate approach based on a generalized estimating equation method was used.At baseline, individuals with the metabolically healthy normal weight (MHNW) phenotype had higher serum fT4 levels (1.2

2018 Thyroid

102. Prevalence of subclinical hypothyroidism in adults visiting primary health-care setting in Riyadh (PubMed)

Prevalence of subclinical hypothyroidism in adults visiting primary health-care setting in Riyadh Background and objectives: Subclinical hypothyroidism is an asymptomatic condition with normal thyroxin and raised thyroid stimulating hormone (TSH) level. The objective of the study was to determine the prevalence of subclinical hypothyroidism in primary health care (PHC) settings in Riyadh and explore the relationship of TSH level with age, gender, family history, body mass index, and co-morbid (...) conditions. Subjects and methods: A cross-sectional study of adult visitors to nine satellites PHC clinics in military housing in Riyadh was carried out. TSH concentration and free T4 levels were measured. Data were collected by nurses and physicians during routine clinical practice in primary care. Descriptive analysis was performed on all variables in study, and relationships were explored using chi-square, t-test, analysis of variance, and linear regression. Results: A total of 340 out of 394

Full Text available with Trip Pro

2018 Journal of community hospital internal medicine perspectives

103. Evaluation of Dose Dependent Maternal Exposure to Bisphenol A on Thyroid Functions in Newborns (PubMed)

functions of newborns are conflicting. The aim of the present study is to demonstrate the effect of different levels of BPA in cord blood on the thyroid functions of newborns, according to gender.The study population included 88 newborns. The BPA levels, Thyroid stimulating hormone (TSH) and free thyroxine (fT4) levels of cord blood were measured. In addition, SPINA-GT (thyroid' incretory capasity), TSH Index (TSHI), standardized TSHI (sTSHI) were calculated and demographic characteristics

Full Text available with Trip Pro

2018 Journal of clinical medicine

104. First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

and ketones by dipstick and Microscopic examination for part C will be reported. Part B: Number of subjects with abnormal Hormone Assessment [ Time Frame: Days -1 and 16 ] Number of subjects with abnormal Hormone Assessments including Luteinizing hormone (LH), Follicle stimulating hormone (FSH), Total Testosterone, Dihydrotestosterone (DHT), Adrenocorticotropic hormone (ACTH), Thyroid stimulating hormone (TSH), cortisol, Triiodothyronine (T3) and Free Thyroxine (T4) will be reported. Part A: Number (...) if the investigator, in consultation with the Medical Monitor, agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Subjects with Body weight >=50.0 kilograms (Kg) (110 lbs.) and body mass index (BMI) within the range 18.5 to 31.0 kilograms per square meter (inclusive). Only male subjects are eligible for this study. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those

2018 Clinical Trials

105. Effect of Evolocumab on Vascular Function

of the study in the judgment of the investigator. Other fibrate therapy (and derivatives) are prohibited Prior use of PCSK9 inhibition treatment other than evolocumab or use of evolocumab < 12 weeks prior to final lipid screening Untreated or inadequately treated hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) < lower limit of normal (LLN) or > 1.5 times the upper limit of normal (ULN), respectively, and free thyroxine (T4) levels that are outside normal range at final (...) ischemic attack (TIA) symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) < 0.85, or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease, or artery stenosis ≥50% by angiography Fasting LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L) or non-HDL-C ≥ 100 mg/dL (≥ 2.6mmol/L) on optimized background lipid lowering therapy (please see Appendix 14.3.) Stable background lipid lowering therapy for at least 4 weeks

2018 Clinical Trials

106. Josef Ressel Centre Perinatal Programming

Index in kg/m^2). Fat mass will be measured by air displacement plethysmography (ADP) system using whole body densitometry to determine body composition (fat and fat-free mass) using a PEA-POD™ and BOD-POD™ (COSMED Company USA). Change in energy content of mature breast milk [ Time Frame: from 8 to 16 weeks of life ] Change in energy content of 3 ml mature breast milk will be determined by MIRIS HMA™ Human Milk Analyzer (Miris Holding AB, Sweden) in kcal/dL. Samples will be measured twice and mean (...) . Breastfeeding in the first year of life appears to be a protective measure against risks for obesity development. Objective: of the "Josef Ressel Centre for Early Life Metabolic Programming of Dispositions of Obesity" is to identify maternal and infant predictors of metabolic risk in childhood obesity. The main considerations of modifiable factors are early infant nutrition, 24-hours-drinking-volume, the velocity of infant weight gain, in relation to infant fat mass and fat free mass, to biomarker

2018 Clinical Trials

107. Chronotropic Incompetence During Exercise in Obese Adolescents: Clinical Implications and Pathophysiology

cholesterol [ Time Frame: day 1 ] blood analyses high-density lipoprotein cholesterol [ Time Frame: day 1 ] blood analyses low-density lipoprotein cholesterol [ Time Frame: day 1 ] blood analyses proteins [ Time Frame: day 1 ] blood analyses triglyceride concentrations [ Time Frame: day 1 ] blood analyses c-reactive proteine [ Time Frame: day 1 ] blood analyses thyroid-stimulating hormone [ Time Frame: day 1 ] blood analyses free thyroxine [ Time Frame: day 1 ] blood analyses cortisol and serum insulin (...) mass index cut-offs for thinness, overweight and obesity) Parental permission Exclusion Criteria: - Chronic cardiovascular, renal, pulmonary and orthopedic disease Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03516721 Locations Layout table

2018 Clinical Trials

108. Adipose Tissue and Serum Inflammation in GH Deficiency

hormone supplements (x 3 months) prior to baseline visit and normal levels of free thyroxine, testosterone in males and normal adrenal function if not on replacement therapy. If female, a. Not pregnant (as evidenced by a negative serum pregnancy test) or lactating and b. If of childbearing potential, agrees to use a medically acceptable form of contraception (such as oral, implantable, or barrier contraception) from the time of screening, for the duration of the study, and for at least one month after (...) adipose tissue biopsy. Adipose tissue parameters will be analyzed in each specimen and then compared to each patient over time as well as to body mass index (BMI)-matched control subjects. Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 60 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Adipose Tissue and Serum Inflammation in Growth Hormone (GH) Deficiency Estimated Study Start Date : May 2019 Estimated

2018 Clinical Trials

109. APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

. ] This outcome will be assessed via blood collection. Cytokine-based pharmacodynamic (PD) biomarkers of APX005M, in combination with nivolumab and cabiralizumab assessed by interferon-gamma levels . [ Time Frame: Change from baseline to 8 weeks. ] This outcome will be assessed via blood collection. Efficacy measured by progression-free survival (PFS) [ Time Frame: From study enrollment up to 6 years. ] PFS will be determined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria v. 1.1. Efficacy (...) measured by overall survival (OS) [ Time Frame: From study enrollment up to 6 years. ] OS will be ascertained by review of the National Death Index, medical records and follow-up phone calls. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research

2018 Clinical Trials

110. Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer

medication Drug: Paclitaxel Chemotherapy medication Drug: Liposomal Doxorubicin Chemotherapy medication Outcome Measures Go to Primary Outcome Measures : Overall survival (OS) [ Time Frame: from randomization to the date of death, assessed up to 44 months ] The combination of pembrolizumab and chemotherapy is expected to increase overall survival with respect to chemotherapy alone Secondary Outcome Measures : Progression free survival (PFS) [ Time Frame: from randomization to the date of radiological (...) /clinical progression of disease or death, assessed up to 44 months ] The combination of pembrolizumab and chemotherapy is expected to increase progression free survival with respect to chemotherapy alone Response rate [ Time Frame: 44 months ] The combination of pembrolizumab and chemotherapy is expected to increase response rate with respect to chemotherapy alone. Adverse events [ Time Frame: 44 months ] Incidence of adverse events, according to the National Cancer Institute Common Toxicity Criteria

2018 Clinical Trials

111. Effects of Infrared Laser Moxibustion on Cancer-related Fatigue in Breast Cancer Patients

count <60,000/μL,hemoglobin <8 g/dL, or leukocyte count<3000/μL) Abnormal findings in a thyroid function test (abnormal level of free thyroxine and thyroid stimulating hormone <0.1 μIU/ml or TSH> 5.1 μIU/ml) Having received acupuncture for any indication in the previous 4 weeks or having received acupuncture test within the past 6 months. Untreated major depressive disorder and suicidal ideations. Pregnant or planning to become pregnant Contacts and Locations Go to Information from the National (...) -7 not significant, 8-10 subclinical, and 11-21 clinically significant depression/anxiety. Stress [ Time Frame: 0week; 3weeks;6weeks; 12weeks; 18weeks ] The Chinese version of 10-Item Perceived Stress Scale (PSS-10) : It is a 10-item instrument and each question is rated on a 5-point Likert scale (0 = never to 4 = very often). A higher score indicates greater stress. Insomnia [ Time Frame: 0week; 3weeks;6weeks; 12weeks; 18weeks ] The Chinese version of the Pittsburgh Sleep Quality Index (PSQI

2018 Clinical Trials

112. Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial

cholesterol ratio) in mg/dl High sensitivity CRP [ Time Frame: 12 months ] High sensitivity CRP in mg/L Quality of Life ratings [ Time Frame: 12 months ] As assessed using IWQoL scale Blood pressure [ Time Frame: 12 months ] Blood pressure in mmHg Heart rate [ Time Frame: 12 months ] Heart rate in beats per minute Hip-waist ratio [ Time Frame: 12 months ] Hip-waist ratio Body Mass Index (BMI) in [ Time Frame: 12 months ] BMI in kg/m^2 Other Outcome Measures: Dose Response Analysis [ Time Frame: 12 months (...) Questionnaire Fat & saturated fat [ Time Frame: 6 & 12 months ] Fat & saturated fat (grams) as assessed by 24 hour dietary recall and Food Frequency Questionnaire Carbohydrate; starchy carbohydrates, sugars, and free sugars [ Time Frame: 6 & 12 months ] Carbohydrate; starchy carbohydrates, sugars, and free sugars (grams) as assessed by 24 hour dietary recall and Food Frequency Questionnaire Fiber [ Time Frame: 6 & 12 months ] Fiber (grams) as assessed by 24 hour dietary recall and Food Frequency

2018 Clinical Trials

113. Pilates Program in Female Adolescent With Eating Disorders

(BIA). Parameters evaluated: Weight (kg); Total Body Water (L); Protein (kg); Minerals (kg); Body Fat Mass (kg); Soft Lean Mass (kg); Fat Free Mass (kg); Skeletal Muscle Mass (kg); Body Mass Index (kg/m2); Percent Body Fat (%); Bone Mineral Contect (kg). Changes in physical fitness - ALPHA-Fitness Battery. [ Time Frame: 3 times (week 0, week 10, week 20). ] ALPHA-Fitness Battery (Assessing Levels of Physical Activity and Fitness) was developed to provide a set of valid, reliable, safe and feasible (...) (perceived body image) and what figure they would like to have (desired body image). The discrepancy between these two classifications represents a measure of body dissatisfaction. The degree of discrepancy varied between -8 and -1 for those who desire a thinner form and between 1 and 8 for those who desire a larger form. A score of 0 was interpreted as satisfaction with body image (Dion et al., 2015). On the other hand, the body image perception index is determined by the following formula: (Estimated

2018 Clinical Trials

114. Liver Function After Intravenous Methylprednisolone Administration

), anti-smooth muscle antibodies (ASMA), anti-mitochondrial antibodies (AMA) and anti-liver kidney-microsomal antibodies (anti-LKM) were also assessed. Thyroid evaluation included measurement of: thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), and serum antithyroid autoantibodies including anti-thyroid peroxidase (aTPO), thyroglobulin antibodies (aTG), thyroid-binding inhibitory immunoglobulin (TBII). According to EUGOGO recommendations: patients with moderate (...) of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03667157 Sponsors and Collaborators Medical University of Warsaw Investigators Layout table for investigator information Principal Investigator: Piotr Miśkiewicz, MD, PhD Medical University of Warsaw More Information Go to Publications automatically indexed to this study

2018 Clinical Trials

115. SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

-free survival for patients with recurrent or new second primary Head and Neck Squamous Cell Carcinoma (HNSCC). Condition or disease Intervention/treatment Phase Head and Neck Squamous Cell Carcinoma (HNSCC) Drug: Pembrolizumab Radiation: Stereotactic Body Radiation Therapy (SBRT) Phase 2 Detailed Description: Safety Run-In: To evaluate the safety of the addition of pembrolizumab (anti PD-1 immunotherapy) to re-irradiation with SBRT for patients with recurrent or new second primary head and neck (...) squamous cell carcinoma (HNSCC). Phase II: To compare progression-free survival (PFS) for patients with recurrent or new second primary head and neck squamous cell carcinoma with SBRT re-irradiation with or without pembrolizumab. OUTLINE: Safety Run-In: Patients receive SBRT over 2 weeks and then receive pembrolizumab every 3 weeks for up to 2 years. Phase II: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive SBRT over 2 weeks and then receive pembrolizumab every 3 weeks for up

2018 Clinical Trials

116. TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

), time to progression (TTP), progression free survival (PFS), overall survival (OS), and alpha-fetoprotein (AFP) response of study participants. II. To evaluate the safety profile of treated patients. OUTLINE: Patients receive TSR-022 and TSR-042 on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 9 weeks. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated (...) of treatment until the date of progression, assessed up to 36 months ] Time from treatment to progression of cancer Progression free survival [ Time Frame: From date of treatment until the date of progression or death, assessed up to 36 months ] Time from treatment to progression of cancer or death Overall survival [ Time Frame: From date of treatment until the date of death, assessed up to 36 months ] Time from treatment to death AFP response [ Time Frame: From treatment start to documentation of AFP

2018 Clinical Trials

117. Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

in breast cancer patients with bone metastases adversely increases the frequency and severity of radiotherapy toxicities including neurological and bone injury. III. To assess fatigue, quality of life, and depression before and after radiotherapy for bone metastases in metastatic breast cancer patients treated with palbociclib. IV. To determine progression free survival (PFS) and overall survival (OS) in breast cancer patients treated with palbociclib and concurrent radiotherapy to bone metastases. V (...) according to International Bone Consensus Guideline Criteria [ Time Frame: At 3 months post-radiation ] Response rate will be estimated as the number of responders divided by the number of patients evaluated for response. Among patients who present with pain, responders will be considered those patients who fulfill the International Bone Consensus response criteria using the BPI item rating maximum pain over the last 3 days at the index site and analgesic usage for the treated site within the last 24

2018 Clinical Trials

118. Mean platelet volume and platelet distribution width levels in patients with mild psoriasis vulgaris with metabolic syndrome (PubMed)

, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, thyroid stimulating hormone, free triiodothyronine, and the free thyroxine levels were evaluated.Mean platelet volume and PDW levels were significantly higher in the mild PV with MetS group compared to the mild PV without MetS group, MetS without PV patients and the healthy control group (p < 0.05, for all). There was no significant difference between the mild PV without MetS (...) group and the healthy control group in terms of MPV and PDW levels (p > 0.05, for all). There was no significant difference between the groups with MetS and without MetS in terms of the psoriasis area and severity index (PASI) (p > 0.05). The PASI was not correlated with MPV and PDW. In addition, metabolic parameters were not correlated with MPV and PDW in mild PV patients.Mean platelet volume and PDW levels showing platelet activation increase significantly in the presence of MetS in patients

Full Text available with Trip Pro

2018 Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

119. Relationship between heart rate variability and subclinical thyroid disorders of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) (PubMed)

and SCHypo were classified by use of medication to treat thyroid disorders, thyrotropin levels respectively above and under the reference range, and normal free thyroxine levels. For HRV, the participants underwent 10 min in supine position and the R-R intervals of the final 5 min were selected for analysis. We first used linear regression models to report crude data and then, multivariate adjustment for sociodemographic (age, sex, and race) and cardiovascular risk factors (hypertension, dyslipidemia (...) , diabetes, smoking, body mass index, use of alcohol, and leisure physical activity) using the euthyroid group as reference. From 9270 subjects (median age, 50; interquartile range: 44-56), 8623 (93.0%) were classified as euthyroid, 136 (1.5%) as SCHyper, and 511 (5.5%) as SCHypo. Compared to euthyroid subjects, SCHyper participants presented significantly higher heart rate (68.8 vs 66.5 for euthyroidism, P=0.007) and shorter R-R intervals (871.4 vs 901.6, P=0.007). Although SCHyper was associated

Full Text available with Trip Pro

2018 Brazilian Journal of Medical and Biological Research

120. Emergence of a latent TSHoma pituitary macroadenoma on a background of primary autoimmune hypothyroidism (PubMed)

were elevated with low normal free thyroxine (T4) levels. Levothyroxine treatment was initiated and the dose was gradually titrated to supraphysiologic doses. This led to the normalisation of her TSH levels but her free T4 and triiodothyronine (T3) levels remained persistently elevated. This prompted a serum prolactin check which returned elevated at 2495 μ/L, leading onto pituitary imaging. A MRI of the pituitary gland revealed a pituitary macroadenoma measuring 2.4 × 2 × 1.6 cm. Despite starting (...) the importance of further investigations with thyroid assay interferences, heterophile antibodies, alpha subunit testing and anterior pituitary profile in cases of resistant and non-resolving primary hypothyroidism. Learning points: •• Levothyroxine treatment in primary hypothyroidism can potentially unmask the presence of a latent TSH-secreting pituitary macroadenoma, which can make diagnosis very challenging. •• A high index of suspicion should prompt clinicians to further investigate cases of primary

Full Text available with Trip Pro

2018 Endocrinology, diabetes & metabolism case reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>